Dr. Salz is currently a Gene Therapy product reviewer at the FDA Center of Biologics Evaluation and Research (CBER). She began her career at the FDA as a Commissioner’s Fellow reviewing cell therapy products and investigating existing manufacturing challenges that could potentially hinder successful commercialization of cell-based products, and strategies that could be useful for establishing product comparability (2016-2018). Dr. Salz is interested in advancing innovative regulatory tools and policies that could enhance rapid clinical development of safe and efficacious cutting-edge therapies. Dr. Salz received a Bachelor of Science in Biotechnology from the University of Bar-Ilan, Israel (2008), and a doctorate degree in Medical Sciences from the University of Florida (2014). During her doctorate, she used molecular and cellular biology tools for discovery of important cancer epigenetic mechanisms. Her post-doctoral work at Johns Hopkins University School of Medicine further focused on discovery of novel epigenetic cancer therapeutic strategies using genomic and gene editing tools.